UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents

Nature medicine, 2020-09, Vol.26 (9), p.1459-1467

2020

Volltextzugriff (PDF)

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

Clinical cancer research, 2017-11, Vol.23 (21), p.6411-6420

2017

Volltextzugriff (PDF)

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy

Haematologica (Roma), 2023-07, Vol.108 (7), p.1793-1802

2023

Volltextzugriff (PDF)

Minimal Residual Disease Tests Provide an Independent Predictor of Clinical Outcome in Adult Acute Lymphoblastic Leukemia

Journal of clinical oncology, 2002-02, Vol.20 (4), p.1094-1104

Mortuza, F. Y.

2002

Volltextzugriff (PDF)

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

American journal of hematology, 2020-02, Vol.95 (2), p.178-187

2020

Volltextzugriff (PDF)

Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia

Blood, 2021-11, Vol.138 (Supplement 1), p.3165-3165

2021

Volltextzugriff (PDF)

Conservation of Substrate Recognition Mechanisms by tRNA Splicing Endonucleases

Science (American Association for the Advancement of Science), 1998-04, Vol.280 (5361), p.284-286

1998

Volltextzugriff (PDF)

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Blood, 2019-11, Vol.134 (Supplement_1), p.895-895

2019

Volltextzugriff (PDF)

Targeting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Humans

Blood, 2019-11, Vol.134 (Supplement_1), p.234-234

2019

Volltextzugriff (PDF)

Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial

Blood, 2018-11, Vol.132 (Supplement 1), p.2680-2680

2018

Volltextzugriff (PDF)

Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia

Journal of clinical oncology, 2002-02, Vol.20 (4), p.1094-1104

2002

Volltextzugriff (PDF)

Trans-acting RNA inhibits tRNA suppressor activity in vivo

RNA (Cambridge), 2002-07, Vol.8 (7), p.904-912, Article S1355838202026031

2002

Volltextzugriff (PDF)

A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARα and T18 oncoproteins

Nature genetics, 1999-11, Vol.23 (3), p.287-295

1999

Volltextzugriff (PDF)

ERRATUM

RNA (Cambridge), 2002-08, Vol.8 (8), p.1090-1090, Article S1355838202029989

2002

Volltextzugriff (PDF)

Conserved Amino Acid Sequences Occur in a Limited Group of CLL Patients with Predominantly Mutated IGH Rearrangements

Blood, 2004-11, Vol.104 (11), p.2000-2000

2004

Volltextzugriff (PDF)

Site selection by the tRNA splicing endonuclease of Xenopus laevis

Cell, 1988-11, Vol.55 (4), p.731-738

1988

Volltextzugriff (PDF)

Interferon Augments PML and PML/RARα Expression in Normal Myeloid and Acute Promyelocytic Cells and Cooperates With All-trans Retinoic Acid to Induce Maturation of a Retinoid-Resistant Promyelocytic Cell Line

Blood, 1996-11, Vol.88 (10), p.3926-3936

1996

Volltextzugriff (PDF)

Binding and cleavage of pre-tRNA by the Xenopus splicing endonuclease: Two separable steps of the intron excision reaction

Cell, 1986-12, Vol.47 (6), p.965-971

1986

Volltextzugriff (PDF)

No mutations in the GATA-1 gene detected in patients with acquired essential thrombocythemia

Haematologica (Roma), 2004-05, Vol.89 (5), p.613

2004

Volltextzugriff (PDF)

BCR-ABL rearrangement is not detectable in essential thrombocythemia

Blood, 2001-04, Vol.97 (7), p.2187-2189

2001

Volltextzugriff (PDF)

BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;q32)

Haematologica (Roma), 2000-09, Vol.85 (9), p.913

2000

Volltextzugriff (PDF)

V(H) gene usage differs in germline and mutated B-cell chronic lymphocytic leukemia

Haematologica (Roma), 2003-11, Vol.88 (11), p.1259

2003

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(37)
Buchkapitel
(1)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Life Sciences & Biomedicine
(20)
Humans
(15)
Animals
(10)
Biological And Medical Sciences
(10)
Female
(9)
Hematology
(9)
Aged
(7)
Base Sequence
(7)
Male
(7)
Medical Sciences
(6)
Oncology
(6)
Adult
(5)
Hematologic And Hematopoietic Diseases
(5)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(5)
Middle Aged
(5)
Molecular Sequence Data
(5)
Endoribonucleases - Metabolism
(4)
Fundamental And Applied Biological Sciences. Psychology
(4)
Mutation
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy

Minimal Residual Disease Tests Provide an Independent Predictor of Clinical Outcome in Adult Acute Lymphoblastic Leukemia

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

Pharmacokinetic / Pharmacodynamic (PK/PD) Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia

Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma

Conservation of Substrate Recognition Mechanisms by tRNA Splicing Endonucleases

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study

Targeting CD70 with Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Humans

Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial

Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial

Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia

Trans-acting RNA inhibits tRNA suppressor activity in vivo

A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARα and T18 oncoproteins

ERRATUM

Conserved Amino Acid Sequences Occur in a Limited Group of CLL Patients with Predominantly Mutated IGH Rearrangements

Site selection by the tRNA splicing endonuclease of Xenopus laevis

Interferon Augments PML and PML/RARα Expression in Normal Myeloid and Acute Promyelocytic Cells and Cooperates With All-trans Retinoic Acid to Induce Maturation of a Retinoid-Resistant Promyelocytic Cell Line

Binding and cleavage of pre-tRNA by the Xenopus splicing endonuclease: Two separable steps of the intron excision reaction

No mutations in the GATA-1 gene detected in patients with acquired essential thrombocythemia

BCR-ABL rearrangement is not detectable in essential thrombocythemia

BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;q32)

V(H) gene usage differs in germline and mutated B-cell chronic lymphocytic leukemia

Suchergebnisse filtern